CD274 and neoplasm: The present review aims to summarize the latest evidence on the association between key components of TME (including PD-L1 and other immune checkpoints, tumor-infiltrating T cells and T cell receptors, cytokines, and extracellular matrix) and the therapeutic responses among mRCC patients with ICI-based treatment and discuss the potential and feasibility of these components as a biomarker for mRCC patients receiving immunotherapy.